Aptamers as Delivery Agents of siRNA and Chimeric Formulations for the Treatment of Cancer

Both aptamers and siRNA technologies have now reached maturity, and both have been validated with a product in the market. However, although pegaptanib reached the market some time ago, there has been a slow process for new aptamers to follow. Today, some 40 aptamers are in the market, but many in c...

Descripción completa

Detalles Bibliográficos
Autores principales: Dinis Ano Bom, Ana Paula, da Costa Neves, Patrícia Cristina, Bonacossa de Almeida, Carlos Eduardo, Silva, Dilson, Missailidis, Sotiris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6956146/
https://www.ncbi.nlm.nih.gov/pubmed/31888119
http://dx.doi.org/10.3390/pharmaceutics11120684

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6956146/
https://www.ncbi.nlm.nih.gov/pubmed/31888119
http://dx.doi.org/10.3390/pharmaceutics11120684

Ejemplares similares